Stock Market Reviews

ELVN (Enliven Therapeutics, Inc.) News

Get the latest news, insights, and market updates on ELVN (Enliven Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Rick Fair as Chief Executive Officer and member of the Board of Directors of Enliven, effective December 11, 2025. Sam Kintz, Co-Founder and former Chief Executive Officer of Enliven, will assume a new role as Head of Pipeline, also effective December 11, 2025. The transition plan
  Dec 11, 2025 - $ELVN
• Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
  Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment.
  Dec 11, 2025 - $ELVN
• Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress
  Enliven Therapeutics (ELVN) has been quietly grinding through its clinical pipeline, and the stock’s recent move offers a useful snapshot of how investors are weighing early trial risk against long term oncology potential. See our latest analysis for Enliven Therapeutics. The latest pullback to a $20.52 share price comes after a solid 1 month share price return of 16.39%. However, the 1 year total shareholder return of negative 15.97% shows longer term sentiment is still cautious, suggesting...
  Dec 9, 2025 - $ELVN
• Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade
  The average of price targets set by Wall Street analysts indicates a potential upside of 101.3% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Dec 3, 2025 - $ELVN
• Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect?
  The mean of analysts' price targets for Enliven Therapeutics, Inc. (ELVN) points to an 87.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Nov 17, 2025 - $ELVN
• /C O R R E C T I O N -- Enliven Therapeutics, Inc./
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update, including highlights of pipeline progress.
  Nov 13, 2025 - $ELVN
• Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
  Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from the ongoing ENABLE Phase 1a/1b clinical trial of ELVN-001 on a subset of chronic myeloid leukemia (CML) patients, specifically in patients with atypical fusion transcripts, at the 67th Annual American Society of Hematology (ASH) 2025 Annual Meeting and Exposition,
  Nov 3, 2025 - $ELVN
• Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum
  Enliven Therapeutics (ELVN) shares have seen some movement lately, with a modest gain over the past month but remaining down for the year. Investors appear to be weighing the company’s longer-term growth prospects in comparison to its recent performance. See our latest analysis for Enliven Therapeutics. Enliven Therapeutics’ 30-day share price return of 7.1% has offered a hint of positive momentum; yet the stock remains firmly in the red for the year, and its one-year total shareholder return...
  Oct 24, 2025 - $ELVN
• Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
  The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
  Sep 12, 2025 - $ELVN
• Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
  Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Sep 9, 2025 - $ELVN